TGF Beta Receptor Market Growth, ALK5 or TGFBR1 or EC 2.7.11.30) - Pipeline Review, H2 2016
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> <strong>Market</strong> <strong>Growth</strong>, <strong>ALK5</strong> <strong>or</strong><br />
<strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) - <strong>Pipeline</strong> <strong>Review</strong>,<br />
<strong>H2</strong> <strong>2016</strong><br />
“The rep<strong>or</strong>t provides in depth analysis on <strong>TGF</strong> <strong>Beta</strong><br />
<strong>Recept<strong>or</strong></strong> Type 1 Activin a <strong>Recept<strong>or</strong></strong> Type II like<br />
Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong>.”<br />
<strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin<br />
<strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong><br />
Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H2</strong> <strong>2016</strong>',<br />
provides in depth analysis on <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein<br />
Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong><br />
Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) targeted<br />
pipeline therapeutics.<br />
The rep<strong>or</strong>t provides comprehensive inf<strong>or</strong>mation on the <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A<br />
<strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine<br />
Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1<br />
<strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>), targeted therapeutics, complete with analysis by indications, stage of<br />
development, mechanism of action (MoA), route of administration (RoA) and molecule type. The<br />
rep<strong>or</strong>t also covers the descriptive pharmacological action of the therapeutics, its complete research<br />
and development hist<strong>or</strong>y and latest news and press releases. Additionally, the rep<strong>or</strong>t provides an<br />
overview of key players involved in <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like<br />
Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase<br />
<strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong><br />
<strong>2.7.11.30</strong>) targeted therapeutics development and features d<strong>or</strong>mant and discontinued projects..<br />
Browse Full Research Rep<strong>or</strong>t @: http://www.radiantinsights.com/research/tgf-betarecept<strong>or</strong>-type-1-activin-a-recept<strong>or</strong>-type-ii-like-protein-kinase-of-53kd<br />
Follow Us:
Rep<strong>or</strong>t features investigational drugs from across globe covering over 20 therapy areas and nearly<br />
3,000 indications. The rep<strong>or</strong>t is built using data and inf<strong>or</strong>mation sourced from proprietary<br />
databases, company/university websites, clinical trial registries, conferences, S<strong>EC</strong> filings, invest<strong>or</strong><br />
presentations and featured press releases from company/university sites and industry-specific third<br />
party sources. Drug profiles featured in the rep<strong>or</strong>t undergoes periodic review following a stringent<br />
set of processes to ensure that all the profiles are updated with the latest set of inf<strong>or</strong>mation.<br />
Additionally, various dynamic tracking processes ensure that the most recent developments are<br />
captured on a real time basis.<br />
The rep<strong>or</strong>t helps in identifying and tracking emerging players in the market and their<br />
p<strong>or</strong>tfolios, enhances decision making capabilities and helps to create effective counter strategies to<br />
gain competitive advantage.<br />
Note:<br />
*Certain sections in the rep<strong>or</strong>t may be removed <strong>or</strong> altered based on the availability and<br />
relevance of data.<br />
*Updated rep<strong>or</strong>t will be delivered in 48 hours of <strong>or</strong>der confirmation.<br />
Request A Sample Copy Of This Rep<strong>or</strong>t at: http://www.radiantinsights.com/research/tgfbeta-recept<strong>or</strong>-type-1-activin-a-recept<strong>or</strong>-type-ii-like-protein-kinase-of-53kd/requestsample<br />
Scope<br />
<br />
<br />
<br />
<br />
The rep<strong>or</strong>t provides a snapshot of the global therapeutic landscape f<strong>or</strong> <strong>TGF</strong> <strong>Beta</strong><br />
<strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin<br />
<strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong><br />
Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong><br />
<strong>2.7.11.30</strong>)<br />
The rep<strong>or</strong>t reviews <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein<br />
Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase<br />
<strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1<br />
<strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) targeted therapeutics under development by companies and<br />
universities/research institutes based on inf<strong>or</strong>mation derived from company and<br />
industry-specific sources<br />
The rep<strong>or</strong>t covers pipeline products based on various stages of development ranging<br />
from pre-registration till discovery and undisclosed stages<br />
The rep<strong>or</strong>t features descriptive drug profiles f<strong>or</strong> the pipeline products which includes,<br />
product description, descriptive MoA, R&D brief, licensing and collab<strong>or</strong>ation details &<br />
other developmental activities<br />
Follow Us:
The rep<strong>or</strong>t reviews key players involved in <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A<br />
<strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong><br />
Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong><br />
<strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) targeted therapeutics and enlists<br />
all their maj<strong>or</strong> and min<strong>or</strong> projects<br />
The rep<strong>or</strong>t assesses <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like<br />
Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein<br />
Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong><br />
<strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) targeted therapeutics based on mechanism of action (MoA),<br />
route of administration (RoA) and molecule type<br />
The rep<strong>or</strong>t summarizes all the d<strong>or</strong>mant and discontinued pipeline projects<br />
The rep<strong>or</strong>t reviews latest news and deals related to <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type 1 (Activin<br />
A <strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong><br />
Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong><br />
<strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) targeted therapeutics<br />
Reasons to Buy<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Gain strategically significant competit<strong>or</strong> inf<strong>or</strong>mation, analysis, and insights to<br />
f<strong>or</strong>mulate effective R&D strategies<br />
Identify emerging players with potentially strong product p<strong>or</strong>tfolio and create effective<br />
counter-strategies to gain competitive advantage<br />
Identify and understand the targeted therapy areas and indications f<strong>or</strong> <strong>TGF</strong> <strong>Beta</strong><br />
<strong>Recept<strong>or</strong></strong> Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin<br />
<strong>Recept<strong>or</strong></strong> Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong><br />
Transf<strong>or</strong>ming <strong>Growth</strong> Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong><br />
<strong>2.7.11.30</strong>)<br />
Identify the use of drugs f<strong>or</strong> target identification and drug repurposing<br />
Identify potential new clients <strong>or</strong> partners in the target demographic<br />
Develop strategic initiatives by understanding the focus areas of leading companies<br />
Plan mergers and acquisitions effectively by identifying key players and it's most<br />
promising pipeline therapeutics<br />
Devise c<strong>or</strong>rective measures f<strong>or</strong> pipeline projects by understanding <strong>TGF</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong><br />
Type 1 (Activin A <strong>Recept<strong>or</strong></strong> Type II Like Protein Kinase Of 53kD <strong>or</strong> Activin <strong>Recept<strong>or</strong></strong><br />
Like Kinase 5 <strong>or</strong> Serine/Threonine Protein Kinase <strong>Recept<strong>or</strong></strong> R4 <strong>or</strong> Transf<strong>or</strong>ming <strong>Growth</strong><br />
Fact<strong>or</strong> <strong>Beta</strong> <strong>Recept<strong>or</strong></strong> Type I <strong>or</strong> <strong>ALK5</strong> <strong>or</strong> <strong>TGF</strong>BR1 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.30</strong>) development<br />
landscape<br />
Develop and design in-licensing and out-licensing strategies by identifying prospective<br />
partners with the most attractive projects to enhance and expand business potential<br />
and scope<br />
See M<strong>or</strong>e Rep<strong>or</strong>ts of This Categ<strong>or</strong>y by Radiant Insights:<br />
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare<br />
Follow Us:
About Radiant Insights,Inc:<br />
Radiant Insights is a platf<strong>or</strong>m f<strong>or</strong> companies looking to meet their market<br />
research and business intelligence requirements. We assist and facilitate<br />
<strong>or</strong>ganizations and individuals procure market research rep<strong>or</strong>ts, helping them in<br />
the decision making process. We have a comprehensive collection of rep<strong>or</strong>ts,<br />
covering over 40 key industries and a host of micro markets. In addition to over<br />
extensive database of rep<strong>or</strong>ts, our experienced research co<strong>or</strong>dinat<strong>or</strong>s also offer a<br />
host of ancillary services such as, research partnerships/ tie-ups and customized<br />
research solutions.<br />
Contact Details:<br />
Michelle Th<strong>or</strong>as<br />
C<strong>or</strong>p<strong>or</strong>ate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Web: http://www.radiantinsights.com/<br />
Visit Our Blog: https://radiantinsightsincblog.w<strong>or</strong>dpress.com/<br />
Follow Us:
Change language